Endoscopically placed fiducial markers for image-guided radiotherapy in preoperative gastric cancer: Technical feasibility and potential benefit

Abstract

Background and study aims Fiducial markers have demonstrated clinical value in radiotherapy in several organs, but little is known about markers in the stomach. Here, we assess the technical feasibility of endoscopic placement of markers in gastric cancer patients and their potential benefit for image-guided radiotherapy (IGRT).

Patients and methods In this prospective feasibility study, 14 gastric cancer patients underwent endoscopy-guided gold (all patients) and liquid (7 patients) marker placements distributed throughout the stomach. Technical feasibility, procedure duration, and potential complications were evaluated. Assessed benefit for IGRT comprised marker visibility on acquired imaging (3–4 computed tomography [CT] scans and 19–25 cone-beam CTs [CBCTs] per patient) and lack of migration. Marker visibility was compared per marker type and location (gastroesophageal junction (i.e., junction/cardia), corpus (corpus/antrum/fundus), and pylorus).

Results Of the 93 marker implantation attempts, 59 were successful, i.e., marker in stomach wall and present during entire 5-week radiotherapy course (2–6 successfully placed markers per patient), with no significant difference (Fisher’s exact test; P>0.05) in success rate between gold (39/66=59%) and liquid (20/27=74%). Average procedure duration was 24.4 min (range 16–38). No procedure-related complications were reported. All successfully placed markers were visible on all CTs, with 81% visible on ≥95% of CBCTs. Five markers were poorly visible (on <75% of CBCTs), possibly due to small marker volume and peristaltic motion since all five were liquid markers located in the corpus. No migration was observed.

Conclusions Endoscopic placement of fiducial markers in the stomach is technically feasible and safe. Being well visible and positionally stable, markers provide a potential benefit for IGRT.

Keywords

Diagnosis and imaging (inc chromoendoscopy, NBI, iSCAN, FICE, CLE) - Endoscopy Upper GI Tract - Dilation, injection, stenting

Publication History

Received: 12 April 2023

Accepted after revision: 13 July 2023

Accepted Manuscript online:
13 July 2023

Article published online:
21 September 2023

• References

• 1 Smalley SR, Benedetti JK, Haller DG. et al. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333 DOI: 10.1200/JCO.2011.36.7136. (PMID: 22585691)
• 2 Cunningham D, Allum WH, Stenning SP. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 DOI: 10.1056/NEJMoa055531. (PMID: 16822992)
• 3 Slagter AE, Jansen EPM, van Laarhoven HWM. et al. CRITICS-II: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 2018; 18: 877 DOI: 10.1186/s12885-018-4770-2. (PMID: 30200910)
• 4 Leong T, Smithers BM, Haustermans K. et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017; 24: 2252-2258 DOI: 10.1245/s10434-017-5830-6. (PMID: 28337660)
• 5 Fernandez DC, Hoffe SE, Barthel JS. et al. Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. Pract Radiat Oncol 2013; 3: 32-39 DOI: 10.1016/j.prro.2012.02.006. (PMID: 24674261)
• 6 Machiels M, Jin P, van Hooft JE. et al. Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers. Acta Oncol (Madr) 2019; 58: 943-950 DOI: 10.1080/0284186X.2019.1588991. (PMID: 30905243)
• 7 Jin P, van der Horst A, de Jong R. et al. Marker-based quantification of interfractional tumor position variation and the use of markers for setup verification in radiation therapy for esophageal cancer. Radiother Oncol 2015; 117: 412-418 DOI: 10.1016/j.radonc.2015.10.005. (PMID: 26475250)
• 8 van der Heide UA, Kotte ANTJ, Dehnad H. et al. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol 2007; 82: 38-45 DOI: 10.1016/j.radonc.2006.11.002.
• 9 Van Der Horst A, Wognum S, Dávila Fajardo R. et al. Interfractional position variation of pancreatic tumors quantified using intratumoral fiducial markers and daily cone beam computed tomography. Int J Radiat Oncol Biol Phys 2013; 87: 202-208 DOI: 10.1016/j.ijrobp.2013.05.001.
• 10 De Ridder M, Gerbrandy LC, de Reijke TM. et al. BioXmark liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: A safety and performance trial. Br J Radiol 2020; 93: 20200241 DOI: 10.1259/bjr.20200241. (PMID: 32463291)
• 11 DiMaio CJ, Nagula S, Goodman KA. et al. EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with videos). Gastrointest Endosc 2010; 71: 1204-1210 DOI: 10.1016/j.gie.2010.01.003.
• 12 Dávila Fajardo R, Lekkerkerker SJ, Van Der Horst A. et al. EUS-guided fiducial markers placement with a 22-gauge needle for image-guided radiation therapy in pancreatic cancer. Gastrointest Endosc 2014; 79: 851-855 DOI: 10.1016/j.gie.2013.12.027.
• 13 Glissen Brown JR, Perumpail RB, Duran JF. et al. Preloaded 22-gauge fine-needle system facilitates placement of a higher number of fiducials for image-guided radiation therapy compared with traditional backloaded 19-gauge approach. Gastrointest Endosc 2021; 94: 953-958 DOI: 10.1016/j.gie.2021.05.035.
• 14 Dhadham G, Hoffe S, Harris C. et al. Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy: safety and technical feasibility. Endosc Int Open 2016; 04: 378-382 DOI: 10.1055/s-0042-100720.
• 15 Rigter LS, Rijkmans EC, Inderson A. et al. EUS-guided fiducial marker placement for radiotherapy in rectal cancer: feasibility of two placement strategies and four fiducial types. Endosc Int Open 2019; 07: 1357-1364 DOI: 10.1055/a-0958-2148. (PMID: 31673605)
• 16 Machiels M, Voncken FEM, Jin P. et al. A novel liquid fiducial marker in esophageal cancer image guided radiation therapy: technical feasibility and visibility on imaging. Pract Radiat Oncol 2019; 9: 506-515 DOI: 10.1016/j.prro.2019.06.018. (PMID: 31279938)
• 17 Chandran S, Vaughan R, Efthymiou M. et al. A pilot study of EUS-guided fiducial insertion for the multidisciplinary management of gastric cancer. Endosc Int Open 2014; 2: 153-159 DOI: 10.1055/s-0034-1377523. (PMID: 26134962)
• 18 Sia J, Glance S, Chandran S. et al. The use of fiducial markers in image-guided radiotherapy for gastric cancer. J Med Imaging Radiat Oncol 2013; 57: 626-628 DOI: 10.1111/1754-9485.12084. (PMID: 24119280)
• 19 Abdelfatah MM, Gochanour EM. Fiducial placement for recurrent gastric cancer. Arab J Gastroenterol 2019; 20: 56-58 DOI: 10.1016/j.ajg.2019.01.007. (PMID: 30745013)
• 20 Machiels M, Van Hooft J, Jin P. et al. Endoscopy/EUS-guided fiducial marker placement in patients with esophageal cancer: A comparative analysis of 3 types of markers. Gastrointest Endosc 2015; 82: 641-649 DOI: 10.1016/j.gie.2015.03.1972.
• 21 Phan VA, Dalfsen R, Le H. et al. Performance of a new preloaded fiducial needle to guide radiation therapy of upper gastrointestinal cancers. Endoscopy 2019; 51: 463-467 DOI: 10.1055/a-0800-0033. (PMID: 30577061)
• 22 Rit S, Wolthaus JWH, Van Herk M. et al. On-the-fly motion-compensated cone-beam CT using an a priori model of the respiratory motion. Med Phys 2009; 36: 2283-2296 DOI: 10.1118/1.3115691. (PMID: 19610317)